Among 551 consecutive recipients of allogeneic bone marrow transplants, 451 survived more than 3 months and were evaluated for chronic graft-versus-host disease (GVHD). Most of the donors were HLA-identical siblings or parents (n = 334). Patients with HLA-mismatched donors (n = 30) and matched unrelated donors (MUD) (n = 87) were also included in the study. In the analysis of all patients, the 5-year cumulative incidence of chronic GVHD was 45%. We analysed 34 risk factors. High recipient age was the single most important risk factor (P Ͻ 0.001). Other significant risk factors in multivariate analysis were: acute GVHD grades I-IV (P Ͻ 0.001), immune female donor to male recipient (P = 0.006) and chronic myelogenous leukaemia (CML), compared with all other diagnoses (P = 0.014). The cumulative 5-year incidence of chronic GVHD, with no significant risk factors present, was 9%, 29% with one risk factor, 53% with two, 68% with three and 75% with all four risk factors present. In patients with HLAidentical sibling donors and GVHD prophylaxis consisting of a combination of methotrexate (MTX) and cyclosporin A (CsA) (n = 208), increasing recipient age (P Ͻ 0.001) and CML (P = 0.007), were found to be significant risk factors for chronic GVHD. Finally, a multivariate analysis in recipients of bone marrow from unrelated donors (n = 89) showed recipient age alone (P = 0.006) to be significantly associated with chronic GVHD.
is associated with prolonged immunodeficiency, predisposing to recurrent and sometimes fatal infections. 4 Most cases are diagnosed between 3 and 4 months after BMT. 3, [5] [6] [7] It follows as an extension of acute GVHD, directly or with a disease-free interval, or it develops de novo without preceding acute GVHD. 3 Affecting some 30-50% of long-term survivors, chronic GVHD constitutes an important clinical problem after BMT. 3, [6] [7] [8] On the other hand, chronic GVHD also has an anti-leukaemic effect (GVL) which, in cases of mild disease, has been shown to improve survival. [9] [10] [11] [12] It is therefore very important to control the degree of chronic GVHD. This should be done not only to protect the patient from severe disease, but also to obtain an optimal GVL effect. In several previous studies, the main risk factor for chronic disease was acute GVHD. 7, 8 Other reported factors include: advanced patient and/or donor age, alloimmune female donor for male recipients, T-replete grafts, combination of pretransplant recipient and donor seropositivity to cytomegalovirus (CMV) and splenectomy. [6] [7] [8] 13 The roles of CMV immunity and infection have been somewhat controversial since some studies have found a positive correlation with chronic GVHD [13] [14] [15] and some have not. 7 In this study, we wished to evaluate and review risk factors for chronic GVHD, in a single-centre setting. We performed a separate analysis in patients treated with cyclosporin A (CsA) combined with methotrexate (MTX), because this is the commonest immunosuppressive protocol used today. 19 ). In 23 patients receiving T cell-depleted marrow, 6 Gy (2 Gy for 3 consecutive days) of total lymph node irradiation (TLI) was given prior to TBI of 7.5 Gy (lungs shielded to receive a median dose of 7 Gy). 20 Patients with SAA received CY (50 mg/kg on each of 4 consecutive days) and, since 1988, this was given in combination with ATG (3-5 mg/kg) for 5 days. Patients with metabolic disorders were given CY (2 g/m 2 ), frequently in combination with Bu (80 mg/m 2 ) although other combinations with TBI have also been used. 21 Before November 1988, all patients with haematological malignancies received 8-12 mg MTX or 20 mg Ara-C intrathecally (i.t.) twice before BMT to prevent CNS leukaemia. Post-transplant, i.t. MTX was given from day 32 and every other week until day 102. After 1988, only patients with ALL, AML, M4 and M5 and/or with a history of CNS disease were given this treatment. To patients with previous CNS disease, i.t. treatment was given until 24 months post-BMT.
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Diagnosis of GVHD
Both acute and chronic GVHD were diagnosed on the basis of clinical symptoms or verified by biopsies (skin, liver, GI tract or oral mucosa). Acute GVHD was graded on a scale from 0 (absent) to IV (severe) using published criteria. 22 Chronic GVHD was classified as limited or extensive. The overall severity was defined as mild, moderate or severe. Mild disease included sicca and minor symptoms from skin and/or liver with a Karnofsky score of 90%. Moderate disease involved symptoms from one or several organs, controlled by immunosuppression, but requiring prolonged or continuous therapy. The Karnofsky score in these patients ranged from 70 to 80%. Severe disease was defined as restricted functions including for instance, malabsorption, severe bronchiolitis, sclerosis of skin, etc, with Karnofsky scores below 70%.
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Prophylaxis of GVHD Sixty-six patients received monotherapy with MTX, according to the Seattle protocol. 22, 24 Forty-four patients were given CsA alone for GVHD prophylaxis. 25 The CsA dose was gradually tapered 6 months after transplantation. One year post-BMT, CsA was discontinued, if no signs of chronic GVHD were found. T cell-depleted bone marrow was given to 23 patients, using previously described techniques. 20, 26 Since August 1985, combination therapy with the first four doses of MTX has been given with CsA, as described above, to 317 patients, 20, 27, 28 with the exception of 73 leukaemic patients, transplanted between May 1989 and January 1993, who continued on MTX treatment post-BMT. 29 To these patients, CsA was given on an individual basis and was tapered after 2 months, if possible. One patient received CsA in combination with prednisolone.
Treatment of GVHD
Acute GVHD grade I was treated with prednisolone 2 mg/kg/day. After 1 week, the dose was gradually tapered, if possible. In more severe cases, ATG, methylprednisolone, MTX or PUVA were used. Several therapeutic strategies were used to treat extensive chronic GVHD including prednisolone, CsA, prednisone on alternate days, 30 azathioprine, 31 PUVA, 32, 33 thalidomide, 34 total lymphoid irradiation 35 and, more recently, extracorporeal PUVA. 36 
Diagnosis of cytomegalovirus (CMV) disease and infection
Patients having a positive blood isolation or in whom CMV DNA was detected in two consecutive leukocyte-based polymerase chain reactions (PCR), while not fulfilling criteria for CMV disease, were diagnosed as CMV infection/reactivation. In all cases of CMV disease, the diagnosis required relevant clinical symptoms from affected organs and, with the exception of retinitis, proof of CMV. 37 
Statistical analysis
Results were analysed as of 9 January 1997. Time to development of chronic GVHD was analysed by the life table method with the log-rank (Mantel-Haenzel) test, taking censored data into account. 38 The Cox regression model was used for uni-and multivariate analyses. 39 Time to chronic GVHD was used to calculate the cumulative incidence curves and death was a censored observation, unless chronic GVHD was present. Only patients surviving at least 90 days after BMT, and therefore at risk of developing chronic GVHD, were included in these analyses. Thirtyfour potential risk factors for development of chronic GVHD were studied (Table 2) . Only factors at the 5% level from the univariate analyses were assessed in the following stepwise multivariate analyses. Patients given monotherapy with MTX or CsA were grouped together, since they show the same incidence of acute and chronic GVHD. 25 For the same reason, patients receiving T cell-depleted grafts were grouped together with those receiving a combination of MTX and CsA as GVHD prophylaxis.
20 Table 2 Univariate analysis of risk factors for chronic GVHD. All patients surviving more than 3 months post BMT were included (n = 451) 
Results
Incidence of chronic GVHD
Among the 451 patients surviving at least 90 days, 56 (12%) had grades II-IV acute GVHD. There were 136 patients (30%) without acute GVHD, 256 patients (57%) with grade I, 42 patients (9%) with grade II and 14 patients (3%) with grade III or IV acute GVHD. Among these 451 surviving patients, 164 (36%) developed chronic GVHD.
The cumulative incidence at 5 years was 45%. In this group of patients with chronic GVHD, 137 (84%) had limited disease and 27 (16%) had extensive disease (17 patients with moderate and 10 with severe disease).
In the subgroup of patients with HLA-identical sibling donors who received a combination of MTX and CsA as GVHD prophylaxis (n = 208), 77 patients (37%) developed chronic GVHD, with a 5-year cumulative incidence of 45%. Furthermore, among recipients of unrelated bone marrow transplants (n = 89), 29 patients (33%) developed chronic GVHD with a cumulative incidence of 48%.
Statistical analysis
In Cox regression univariate analysis of all 451 patients, 19 risk factors were significantly associated with chronic GVHD, as depicted in Table 2 . These factors were included in the subsequent multivariate analysis. Significant risk factors in multivariate analysis are shown in Table 3 . The cumulative incidence of chronic GVHD in patients with preceding grades I-IV acute GVHD was 51 vs 25% in patients with no acute GVHD (P Ͻ 0.001). CML patients showed a cumulative incidence of chronic GVHD of 64%, compared to 36% in patients with acute leukaemia (P Ͻ 0.001). In male recipients with immunized female donors, 61% developed chronic GVHD, as compared to 40% in all other recipients (P Ͻ 0.001). The incidence of chronic GVHD increased with an increasing number of risk factors as follows: 29% with one risk factor, 53% with two, 68% with three and 75% with all four risk factors present ( Figure  1 ). It is notable that neither CMV infection nor disease was Years after BMT Probability of chronic GVHD Chronic GVHD Figure 1 Probability and time to chronic GVHD in patients with 0 to 4 significant risk factors (rf) present (Table 3 ). The probability of chronic GVHD increased with the number of risk factors.
Table 4
Multivariate analysis in patients with HLA-identical related donors and immunosuppression with MTX combined with CsA (n = 208) (significant risk factors P Ͻ 0.05) significantly associated with chronic GVHD in this multivariate analysis. When analysing the subgroup of patients with HLAidentical sibling donors and GVHD prophylaxis with the MTX/CsA combination (n = 208), we found the following factors to be significant in the univariate analysis: recipient age (P Ͻ 0.001), donor age (P Ͻ 0.001), CML (P Ͻ 0.001), malignant disease (P = 0.003), acute GVHD grades I-IV (P = 0.005), using a female donor for a male recipient (P = 0.005), booster cell therapy (P = 0.017), donor/recipient sex mismatch (P = 0.020), donor seropositivity to 3-4 herpes viruses (P = 0.024), donor VZV serology (P = 0.040), recipient and donor HSV seropositivity (P = 0.040) and immunized female donor to a male recipient (P = 0.044). In this more homogeneous group, advanced recipient age and CML, in comparison with all other diagnoses, were the only two significant risk factors for chronic GVHD in multivariate analysis (Table 4) (Figures 2 and 3) .
Co
Finally, we analysed risk factors for chronic GVHD in 89 recipients of unrelated marrow transplants. Recipient age (P = 0.006), CML (P = 0.004), and malignant disease as compared to all other diagnoses (P = 0.03), were significant factors in univariate analysis. In multivarate analysis, only recipient age was significantly associated with chronic GVHD (Table 5) .
Discussion
Analysing all patients, we found that advanced recipient age, acute GVHD grades I-IV, CML and alloimmune female donor to male recipient were significant risk factors for chronic GVHD. In previous studies, recipient and donor age have been found to be important risk factors for developing chronic GVHD. [6] [7] [8] Atkinson et al 7 showed, in 2534 patients reported to the IBMTR, that donor and recipient age are highly correlated factors (r = 0.85). Their study, like ours, showed high recipient age to be the strongest risk factor for chronic GVHD, in patients with no or grade I acute GVHD. A previous study from our centre showed donor age to be of greater significance than recipient age. 6 It is difficult to be certain which is biologically more important, because donor and recipient age are correlated in HLA-identical siblings. The strong association between acute and chronic GVHD is well known from several studies. [6] [7] [8] 13 In most of these, only grades II-IV acute GVHD have been significantly associated with chronic GVHD. 6, 8, 13 However, our study confirms the findings of Atkinson et al 7 that any grade of acute GVHD results in an increased risk of chronic GVHD. It is well established that immunosuppression with MTX, combined with CsA, results in a lower incidence of acute 16, 17, 28, 40 and chronic GVHD. 16 We believe that the use of this regimen, in the majority of our patients, is one reason why acute GVHD is of somewhat Table 5 Multivariate analysis in patients with unrelated donors (n = 89) (significant risk factors P Ͻ 0.05) less importance for the development of chronic GVHD in our patients, compared to previous reports. This is also confirmed in our analysis of patients with HLA-identical sibling donors and GVHD prophylaxis, using the combination of MTX/CsA. In this more homogeneous group, acute GVHD was not a significant risk factor for chronic GVHD in multivariate analysis. A previous study from the IBMTR by Gale et al 41 showed that an alloimmune female donor for a male recipient was the strongest predictor of acute GVHD. This risk factor has also been reported significant for de novo chronic GVHD 7 and is confirmed in our study. The fourth largest risk factor we found, when analysing all patients, was CML in comparison with all other diagnoses. Boström et al 13 found CML to be a significant risk factor in univariate analysis only and posed the hypothesis that this was due to a high frequency of splenectomy in CML patients. However, splenectomy was not a significant risk factor in the present analysis. Otherwise, CML has not previously been reported as a risk factor for chronic GVHD. Patients with CML are usually above mean age for BMT, and in that respect they run an increased risk of chronic GVHD. However, in our study we found CML to be a significant risk factor, independent of patient age. Donor leukocyte transfusions are increasingly used to induce remission in patients with leukaemic relapse and have proven effective, especially in patients with CML. 42 This treatment may induce chronic GVHD. However, in the present analysis, treatment with donor leukocyte transfusions was not associated with an increased risk of chronic GVHD. Some patients with CML have received interferon alpha prior to BMT. This drug increases the expression of cell surface adhesion molecules, which may increase the risk of GVHD. 43 However, this may not be the case, at least for acute GVHD. A previous study from our centre showed no increased risk of acute GVHD in patients with CML as compared to other diagnoses. 44 At our centre, we have seen a lower risk of leukaemic relapse in patients with CML, as compared to acute leukaemia. 45 This may be explained by the higher incidence of chronic GVHD among CML patients, in turn contributing to the favourable outcome in CML patients receiving unrelated bone marrow. 46 The role of CMV in the development of chronic GVHD has been controversial. Seropositivity in the donor 15 and seropositivity in both donor and recipient 13 have been shown to correlate with chronic GVHD. Lönnqvist et al 14 found a positive correlation between CMV infection and chronic GVHD in a previous study from our centre. However, this was not confirmed in two studies. 6, 7 CMV infection was significant in our univariate analysis (Table 1) , but did not maintain its significance in the multivariate analysis. The discrepancy between this study and previous reports from our centre may be that methods for CMV diagnosis have changed with time. In more recent years, PCR diagnosis has been used, which detects CMV DNA and does not necessarily mean that protein synthesis occurs.
Our analysis of patients with HLA-identical sibling donors and GVHD prophylaxis with a MTX/CsA combination showed only increasing recipient age and CML to be significantly associated with chronic GVHD. Acute GVHD grades I-IV were a significant risk factor in univariate analysis, but had no predictive value in multivariate analysis for these patients. Among patients treated with MTX + CsA, the incidences of chronic GVHD were similar around 50% in recipients of marrow from HLA-identical siblings and recipients of MUD marrow. One might expect that recipients of unrelated marrow would run an increased risk of chronic GVHD. The reasons why this was not the case may be that MUD marrow recipients were given ATG during conditioning, which may reduce the incidence of acute GVHD, this being around 20%. Furthermore, CSA was given during the first year to all recipients of unrelated marrow, while in HLA-identical siblings it was discontinued as soon as possible after 2 months, in the absence of GVHD.
Finally, in the analysis of patients with unrelated donors, increasing recipient age was the only significant risk factor for chronic GVHD in multivariate analysis. Therefore, prolonged immunosuppression may be considered in elderly patients.
